ASMB Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 geg. 2024 @ 23:00):

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States...

Stats
Šios dienos apimtis	23 422.00
Vidutinė apimtis	19 495.00
Rinkos kapitalizacija	82.48M
EPS	$0 ( 2024-05-09 )
Kita pelno data	( $-3.23 ) 2024-05-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.120
ATR14	$0.106 (0.71%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-29	White Nicole S	Buy	3 333	Common Stock
2024-04-30	White Nicole S	Sell	1 255	Common Stock
2024-04-29	Okazaki Jason A	Buy	4 166	Common Stock
2024-04-30	Okazaki Jason A	Sell	1 569	Common Stock
2024-04-29	Delaney William E Iv	Buy	3 333	Common Stock

INSIDER POWER
65.17
Last 96 transactions
Buy: 3 858 062 \| Sell: 644 587

Tūris Koreliacija

Ilgas: 0.14 (neutral)

Trumpas: -0.30 (neutral)

Signal:(55.621) Neutral

Assembly Biosciences Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
KBWP	0.917
BUFF	0.909
DVOL	0.906
TARS	0.906
CRDL	0.903
FNILX	0.896
DXJS	0.896
MMYT	0.896
CDRO	0.895
FLXS	0.893

10 Labiausiai neigiamai susiję koreliacijos
GP	-0.911
MYMD	-0.891
SINT	-0.891
TBLT	-0.89
AGRX	-0.889
AGFY	-0.884
RIVN	-0.883
WW	-0.882
ACON	-0.882
FLGT	-0.88

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Assembly Biosciences Inc Koreliacija - Valiuta/Žaliavos

-0.16
( neutral )

-0.14
( neutral )

0.00
( neutral )

-0.27
( neutral )

-0.35
( neutral )

-0.40
( neutral )

Assembly Biosciences Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$7.16M
Bruto pelnas:	$6.71M (93.72 %)
EPS:	$-13.38

FY	2023
Pajamos:	$7.16M
Bruto pelnas:	$6.71M (93.72 %)
EPS:	$-13.38

FY	2022
Pajamos:	$0
Bruto pelnas:	$-498 000 (0.00 %)
EPS:	$-22.82

FY	2021
Pajamos:	$6.25M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-3.67

Financial Reports:

No articles found.

Assembly Biosciences Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Assembly Biosciences Inc

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.